Growth hormone (GH) and IGF-I assays: Methodological aspects and its implications in acromegaly diagnosis and follow-up;Ensaios para a medida de hormônio do crescimento (GH) e IGF-I: Aspectos metodológicos e suas implicações no diagnóstico e seguimento da acromegalia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 4, 2007, Pages 511-519

  Casagrande, Alessandra ^a   Czepielewski, Mauro A ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Acromegaly; Diagnosis; Growth hormone; Immunoassays

Indexed keywords

EID: 34547903604     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000400003     Document Type: Review

References (50)

1. Baumann G, Winter RJ, Shaw M. Circulating molecular variants of growth hormone in childhood. Pediatr Res 1987;22:21-2.
2. Kopchick JJ, Andry JM. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab 2000;71:293-314.
3. Baumann G. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 1999;51(suppl. 1):2-6.
4. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12:424-49.
5. Wood P. Growth hormone: its measurement and the need for assay harmonization. Ann Clin Biochem 2001;38:471-82.
6. Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme. Horm Res 1999;51(suppl. 1):13-9.
7. Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 1997;43:950-6.
8. Baumann G, Amburn K, Shaw MA. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 1988;122:976-84.
9. Mannor DA, Winer LM, Shaw MA, Baumann G. Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J Clin Endocrinol Metab 1991;73:30-4.
10. Kratzsch J, Selisko T, Birkenmeier G. Identification of transformed alpha 2-macroglobulin as a growth hormone-binding protein in human blood. J Clin Endocrinol Metab 1995;80:585-90.
11. Baumann G, Stolar MW. Molecular forms of human growth hormone secreted in vivo: nonspecificity of secretory stimuli. J Clin Endocrinol Metab 1986;62:789-90.
12. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA 2002;99:9858-63.
13. Gent J, Van Den Eijnden M, Van Kerkhof P, Strous GJ. Dimerization and signal transduction of the growth hormone receptor. Mol Endocrinol 2003;17:967-75.
14. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-9.
15. Cuttler L. The regulation of growth hormone secretion. Endocrinol Metab Clin North Am 1996;25:541-71.
16. Lengyel AM. Novel mechanisms of growth hormone regulation: growth hormone-releasing peptides and ghrelin. Braz J Med Biol Res 2006;39:1003-11.
17. Wieringa GE, Barth JH, Trainer PJ. Growth hormone assay standardization: a biased view? Clin Endocrinol (Oxf) 2004;60:538-9.
18. Bristow AF. International standards for growth hormone. Horm Res 1999;51(suppl. 1):7-12.
19. Boguszewski CL. Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 2003;26:274-88.
20. Miles LE, Hales CN. Labelled antibodies and immunological assay systems. Nature 1968;219:186-9.
21. Celniker AC, Chen AB, Wert RM, Jr., Sherman BM. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989;68:469-76.
22. Costa AC, Rossi A, Martinelli CE, Jr., Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002;87:3142-7.
23. Stoffel-Wagner B, Springer W, Bidlingmaier F, Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol (Oxf) 1997;46:531-7.
24. Freda PU. Pitfalls in the biochemical assessment of acromegaly. Pituitary 2003;6:135-40.
25. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16.
26. Lindholm J, Giwercman B, Giwercman A, Astrup J, Bjerre P, Skakkebaek NE. Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol (Oxf) 1987;27:553-62.
27. Blethen SL, Chasalow FI. Use of a two-site immunoradiometric assay for growth hormone (GH) in identifying children with GH-dependent growth failure. J Clin Endocrinol Metab 1983;57:1031-5.
28. Reiter EO, Morris AH, MacGillivray MH, Weber D. Variable estimates of serum growth hormone concentrations by different radioassay systems. J Clin Endocrinol Metab 1988;66:68-71.
29. Barkan AL. Biochemical markers of acromegaly: GH vs. IGF-I. Growth Horm IGF Res 2004;14(suppl. A):S97-100.
30. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312-9.
31. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ, Shalet SM. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab 2003;88:5865-70.
32. De P, Rees DA, Davies N, John R, Neal J, Mills RG, et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 2003;88:3567-72.
33. Serri O, Beauregard C, Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. J Clin Endocrinol Metab 2004;89:658-61.
34. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Clin Endocrinol Metab 2004;89:1613-7.
35. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005;90:4081-6.
36. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, et al. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 2006;65:250-6.
37. Daughaday WH, Starkey RH, Saltman S, Gavin JR, 3rd, Mills-Dunlap B, Heath-Monnig E. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 1987;65:617-23.
38. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-96.
39. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979;301:1138-42.
40. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74.
41. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67:69-73.
42. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit and growth hormone binding protein levels. J Clin Endocrinol Metab 2005;90(12):6480-9.
43. Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, et al. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab 1986;63:1348-53.
44. Dobrashian RD, O'Halloran DJ, Hunt A, Beardwell CG, Shalet SM. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol (Oxf) 1993;38:589-93.
45. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002;87:3537-42.
46. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004;89:495-500.
47. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, et al. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol (Oxf) 2005;62:410-7.
48. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721.
49. Chowen JA, Frago LM, Argente J. The regulation of GH secretion by sex steroids. Eur J Endocrinol 2004;151(suppl. 3):U95-100.
50. Clemmons DR. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 2001;55(suppl. 2):73-9.